Doctors react to alleged Trump health concerns as photos show swelling and bruising
In an "effort of transparency" on Thursday, White House Press Secretary Karoline Leavitt shared a note from Trump's physician after he underwent a "comprehensive examination" by the White House Medical Unit.
During a press briefing, Leavitt stated that Trump's swollen legs were part of a "benign and common condition" called "chronic venous insufficiency" that can affect older individuals. (The president is 79.)
"Importantly, there was no evidence of deep vein thrombosis or arterial disease," she said.
Leavitt attributed the bruising on the president's hand to "frequent handshaking and the use of aspirin."
"This is consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen," she said.
"This is a well-known and benign side effect of aspirin therapy, and the president remains in excellent health."
Scott A. Sundick, M.D., a vascular and endovascular surgeon at The Cardiovascular Care Group in Westfield, New Jersey, commented on the concerns that have been raised. (He has not treated the president.)
"Leg swelling is a common condition, particularly among older adults. As a practicing vascular surgeon, I see patients for this issue more frequently than almost any other complaint," he told Fox News Digital.
"The president remains in excellent health."
While leg swelling is often benign, it can sometimes be a symptom of serious, potentially life-threatening conditions, such as acute deep vein thrombosis (DVT), congestive heart failure (CHF) or renal failure, according to the doctor.
"In the president's case, these more concerning causes were appropriately ruled out through a combination of diagnostic testing, including a venous Doppler ultrasound, echocardiogram and laboratory evaluations respectively," he added.
Sundick also spoke about the president's diagnosis of chronic venous insufficiency, which he described as a "relatively common and benign condition."
"Under normal circumstances, blood returns to the heart from the legs through the veins, aided by the contraction of leg muscles with each step we take," he said.
"These contractions help push blood upward, and valves within the veins prevent it from flowing backward toward the feet. When these valves become weakened or incompetent, blood can pool in the lower legs — a condition known as venous insufficiency."
This condition can cause symptoms such as leg swelling or varicose veins, the doctor noted.
Treatment usually includes the use of compression stockings or, in some cases, a minimally invasive outpatient procedure called venous ablation.
Regarding the bruising being attributed to aspirin therapy, Sundick noted that many older adults take daily low-dose aspirin as part of a cardiovascular disease prevention strategy.
"Aspirin works by inhibiting platelet function, reducing the risk of blood clots that could lead to heart attacks or strokes," he said.
"A well-known side effect of aspirin therapy is an increased tendency to bruise easily, even with minor trauma."
Sundick said this is "common and generally not concerning," particularly considering aspirin's "well-established cardiovascular benefits."
Dr. Marc Siegel, Fox News' senior medical analyst, also commented on the bruising seen on Trump's hand.
"As you age, your skin can become more friable (fragile), less elastic and more prone to easy bruising," Siegel, who has not treated the president, told Fox News Digital.
"I don't think there's anything hidden there at all."
"Aspirin interferes with platelet function, making this more likely."
On a Thursday episode of "America Reports," Siegel noted that he found the medical update "reassuring," calling Trump's condition "not serious, completely benign and cosmetic."
"It's expected for a man who's in his late 70s and standing on his feet all the time," Siegel added, noting that compression stockings and elevating the legs could help to reduce swelling and any potential discomfort.
For more Health articles, visit www.foxnews.com/health
The doctor also said he "accepts the explanation" that Trump's hand bruising is caused by "vigorous handshaking."
"I don't think there's anything hidden there at all," Siegel said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
Hemophilia B: Gene Therapy Shows 5-Year Success
TOPLINE: A single intravenous dose of etranacogene dezaparvovec gene therapy maintained factor IX (FIX) activity at 45.7 IU/dL after 5 years in patients with hemophilia B, eliminating the need for prophylaxis with no late-emergent safety events. METHODOLOGY: Researchers conducted a phase 2b, open-label, single-arm, multicenter trial evaluating a single intravenous dose (2 × 10 13 genome copies/kg) of etranacogene dezaparvovec in three adult participants with severe or moderately severe hemophilia B (FIX ≤ 2%). genome copies/kg) of etranacogene dezaparvovec in three adult participants with severe or moderately severe hemophilia B (FIX ≤ 2%). Primary endpoint assessment measured FIX activity ≥ 5 IU/dL at 6 weeks, while secondary endpoints included bleeding frequency, FIX concentrate use, and adverse events over 5 years of follow-up. Participants were positive for preexisting adeno-associated virus serotype 5 neutralizing antibodies, with a mean titer of 25 at dosing, and received FIX recovery assessment before administration. Analysis included weekly FIX level assessments for 6 weeks, followed by biweekly until week 26, monthly until month 12, and twice-yearly up to month 60, along with quality-of-life assessments using Hem-A-QoL. TAKEAWAY: Mean FIX activity increased to 40.8 IU/dL (range, 31.3-50.2) at year 1 and was maintained at 45.7 IU/dL (range, 39.0-51.2) at year 5, with two participants achieving levels in the nonhemophilia range (≥ 40 IU/dL). Mean annualized bleeding rate decreased to 0.14 for the cumulative follow-up period over 5 years, with two participants experiencing no bleeds throughout the study period. All participants discontinued and remained free of FIX prophylaxis after treatment, with only one participant requiring episodic FIX replacement therapy for elective surgeries and two bleeding episodes. No clinically significant elevations in liver enzymes, requirement for steroids, FIX inhibitor development, thrombotic complications, or late-emergent safety events were observed in any participant over the 5-year period. IN PRACTICE: 'Five years after administration, etranacogene dezaparvovec was effective in adults with hemophilia B with a favorable safety profile. Participants are eligible to participate in an extension study for 10-year additional follow-up,' wrote the authors of the study. SOURCE: The study was led by Annette von Drygalski, MD, Division of Hematology/Oncology, Department of Medicine, University of California San Diego. It was published online in Blood Advances. LIMITATIONS: According to the authors, while the study demonstrated sustained efficacy and safety, the small sample size of only three participants limits the generalizability of the findings. The researchers noted that longer-term follow-up studies are needed, and all participants have enrolled in an extension study for an additional 10 years to further evaluate the durability and safety of the treatment. DISCLOSURES: The study was supported by CSL Behring. Drygalski disclosed serving as a consultant for BioMarin, Regeneron, Pfizer, Bioverativ/Sanofi, Sobi, CSL Behring, Novo Nordisk, Pfizer, Spark Therapeutics, Takeda, Genentech, and uniQure and being a cofounder and member of the board of directors of Hematherix LLC. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
5 hours ago
- Yahoo
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
San Francisco Chronicle
7 hours ago
- San Francisco Chronicle
Planned Parenthood closes 5 Northern California clinics, citing Trump budget bill
President Donald Trump's budget cuts to Medicaid have forced Planned Parenthood Mar Monte to shutter five clinics across Northern California and the Central Coast, including one in South San Francisco, the group said Thursday. The GOP-led federal spending bill that Trump signed into law earlier this month eliminated federal Medicaid funding for any type of medical care to organizations that perform abortions. Mar Monte is the largest Planned Parenthood affiliate in the country, with health care centers from Bakersfield, the Bay Area, Stockton and Sacramento. The now-shuttered facilities also include San Mateo, Santa Cruz, Gilroy and Madera. The closures represent the first wave of how the recent federal budget cuts will have real-life consequences for health clinics across the country — particularly for low-income Americans. They are also a crushing blow to a state that set it up to be an abortion haven after the U.S. Supreme Court overturned Roe v. Wade in 2022. In the year after the decision, political leaders in California — led by Gov. Gavin Newsom and the Democratic-controlled Legislature — passed more than a dozen new laws and invested more than $200 million to increase access across the state. Thursday's announcement drives home the extent of the federal government's tremendous power to impact abortion access. Roughly 80% of Mar Monte's patients received Medi-Cal, California's version of Medicaid. Ten million people are expected to lose their health insurance because of nearly $1 trillion in Medicaid cuts over the next decade in the One Big Beautiful Bill Act, according to the nonpartisan Congressional Budget Office. Meanwhile, the wealthiest Americans will receive a disproportionate share of the tax cuts funded by those cuts, according to the Center for Budget and Policy Priorities. In just one week since Mar Monte stopped billing Medicaid, the Planned Parenthood affiliate with 35 locations said it saw 5,000 patients — amounting to about $1.7 million in care costs it covered without reimbursement — Mar Monte Chief of Staff Andrew Adams told the Chronicle Thursday. 'It's just not sustainable,' said Adams. 'We can't keep our doors open if we continue doing that.' Mar Monte said the funding law also forced it to end services in family medicine, behavioral health and prenatal care. The Planned Parenthood affiliate estimates it will lose $100 million in annual revenue from care that can no longer be reimbursed under the law because they provide abortion care. Americans tend to support abortion rights, according to public polling. A May 2025 Gallup Poll found that 51% of respondents described themselves as 'pro choice' while 43% described themselves as 'pro life.'Of those respondents who said they were 'dissatisfied' with the nation's abortion polices, 42% said they would like to see them made 'less strict' while 14% wanted them to be 'stricter.'
